Abstract

Nifedpine in Compounded Oral and Topical Preparations

Author(s): McCluskey Susan V, Brunn Gregory J

Issue: Mar/Apr 2011 - Volume 15, Number 2

Page(s): 166-169

Download in electronic PDF format for $75
  • Nifedpine in Compounded Oral and Topical Preparations Page 1
  • Nifedpine in Compounded Oral and Topical Preparations Page 2
  • Nifedpine in Compounded Oral and Topical Preparations Page 3
  • Nifedpine in Compounded Oral and Topical Preparations Page 4

Abstract

The purpose of this study was to evaluate nifedipine oral and topical compounding formulas and procedures. Topical preparations were compounded in Plastibase 50 W, using combinations of two drug sources and four types of light exposure. Oral preparations were compounded using combinations of two drug sources, two types of light exposure, and four suspending vehicles. Drug sources consisted of the contents of commercial nifedipine soft-gelatin capsules and nifedipine powder USP. Light exposures were ambient, red-shaded, goldshaded fluorescent light, or a combination of ambient and gold-shaded fluorescent light. Topical formulations were assessed for potency, uniformity, and usability characteristics such as acceptable look and feel of the preparation. Oral formulations were assessed for potency, uniformity, and usability characteristics, such as acceptable look and taste of the preparation. Preparations which were compounded, in entirety, under gold-shaded fluorescent light with nifedipine powder USP as the drug source resulted in a potency of 90% to 110% of intended value. Preparations that were exposed to ambient or red-shaded fluorescent light at any time in the compounding procedure resulted in subpotent preparations. Nifedipine is sensitive to certain wavelengths of light resulting in rapid degradation. When exposed to fluorescent room light, significant degradation may occur in a time frame less than what may be required to compound a preparation, necessitating the need for compounding to take place under a spectrum of light that will not degrade the drug. Gold fluorescent lighting appears to prevent nifedipine degradation during compounding procedures. Concerning the drug source, the use of commercial nifedipine soft gelatin capsules was problematic, while nifedipine powder USP is a suitable choice for the active pharmaceutical ingredient.

Related Keywords

  • nifedipine
  • calcium channel blocker
  • hypertension
  • high blood pressure
  • angina
  • photodegradation
  • degradation
  • light exposure
  • potency
  • stability
  • topical preparations
  • oral preparations
  • light sensitivity
  • vehicle

Related Categories

  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • CARDIOLOGY
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2011
Pg. 166-169
Nifedpine in Compounded Oral and Topical Preparations
Author(s): McCluskey Susan V, Brunn Gregory J
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
May/Jun 2020
Pg. 200-205
Quality Control: Photostability of Compounded Preparations
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Jul/Aug 2021
Pg. 344-351
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Sep/Oct 2011
Pg. 435-437
Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations
Author(s): Yamreudeewong Weeranuj, Dolence Eric Kurt, Teixeira M Glaucia
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
Jul/Aug 2013
Pg. 307-311
Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
Author(s): McElhiney Linda F
Sep/Oct 2018
Pg. 387-398
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Author(s): Ashe Krystina, Baskett Dustin
Nov/Dec 2020
Pg. 501-508
Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Jan/Feb 2002
Pg. 34-37
Basics of Compounding Biotechnologic Preparations
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 167-175
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure
Author(s): Ip Kendice, Banov Daniel, Bassani Gus, Morgan Latisha
Mar/Apr 2016
Pg. 155-158
Utilization of Compounded Medications in an Oral Medicine Practice
Author(s): Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
May/Jun 2022
Pg. 219-228
Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 270-274
A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Author(s): Riepl Mike
Mar/Apr 2016
Pg. 159-163
Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups
Author(s): Kirk Loren, Lewis Paul, Luu Yao, Brown Stacy
Sep/Oct 2011
Pg. 422
Nifedipine 1-mg/500-mg Oral Powder
Author(s): Allen Loyd V Jr
Sep/Oct 2011
Pg. 423
Nifedipine 10-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2006
Pg. 303
Nifedipine 4-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Mar/Apr 2021
Pg. 131-139
Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Author(s): Allen Loyd V Jr